The chromatin-modifying histone deacetylases (HDACs) remove acetyl groups from acetyl-
lysine residues in histone amino-terminal tails, thereby mediating transcriptional repression …

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of
neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor …

Nonselective histone deacetylase (HDAC) inhibitors show dose-limiting side effects due to
the inhibition of multiple, essential HDAC subtypes that can be limited or prevented by …

A promising means in the search of new small molecules for the treatment of
schistosomiasis (amongst other parasitic ailments) is by targeting the parasitic epigenome …

Emerging evidence supports that altered α-tubulin acetylation occurs in Parkinson's disease
(PD), a neurodegenerative disorder characterized by the deposition of α-synuclein fibrillary …

In this study, a series of novel HDAC inhibitors, using 1, 2, 4-oxadiazole-containing as the
cap group, were synthesized and evaluated in vitro. Compound 14b, N-hydroxy-2-(methyl …

Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of
various human diseases including cancer, neurodegenerative disease and immunology due …

Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone
deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing …

The enzyme cofactor (R)-lipoic acid plays a critical role in central carbon metabolism due to
its catalytic function in the generation of acetyl-CoA, which links glycolysis with the …

The design of multi-target drugs acting simultaneously on multiple signaling pathways is a
growing field in medicinal chemistry, especially for the treatment of complex diseases, such …